Please wait

Exhibit 10.23

 

December 30, 2025

 

Steven Perrin

 

Re: Voluntary Cancellation of Certain Option Grants

 

Dear Dr. Perrin,

 

Eledon Pharmaceuticals, Inc. (the “Company”) has granted you an award or multiple awards of stock options under one of the Company’s long-term equity incentive plans. You have volunteered to forfeit for no consideration the stock option awards listed in the table below (the “Forfeited Options”):

 

Option Grant Number

Option Grant Date

Option Expiration Date

Option Exercise Price

Option Vested or Unvested

Performance or Time-Based Option

Total Number of Options Being Forfeited

389

01/29/2020

01/29/2030

$8.91

61,831

Time-Based

61,831

390

01/01/2019

01/29/2030

$8.91

118,097

Time-Based

118,097

391

11/19/2019

01/29/2030

$8.91

142,833

Time-Based

142,833

373

09/14/2020

09/13/2030

$9.00

436,467

Time-Based

436,467

403

01/01/2019

09/08/2030

$6.85

606,316

Time-Based

606,316

 

 

You hereby agree that you are voluntary forfeiting the Forfeited Options in exchange for your continued employment or service with the Company, and that the Forfeited Options are not (1) being canceled, exchanged, or surrendered in exchange for cash or other awards for the purpose of repricing the Forfeited Options, or (2) being canceled, exchanged, or surrendered for a new option or SAR award with an exercise or base price that is less than the exercise or base price of the Forfeited Options.

 

Except for the Forfeited Options, all of your other outstanding stock options granted by the Company shall remain outstanding in accordance with their terms

 

This agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. This agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.

 

***


 

 

 

 

 

Sincerely,

 


Exhibit 10.23

 

 

Eledon Pharmaceuticals, Inc.

 

 

_/s/ David-Alexandre C. Gros, M.D.

By: David-Alexandre Gros

Title: Chief Executive Officer

 

 

 

 

Acknowledged and Agreed:

 

 

_____/s/ Steve Perrin, Ph.D_______

Steven Perrin